BiotechTube

mRNA-1083.1

Phase 2Completed
0 views this week 0 watching
0
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV-2, Influenza

Conditions

SARS-CoV-2, Influenza

Trial Timeline

Apr 14, 2023 → Dec 3, 2024

NCT ID
NCT05827926

About mRNA-1083.1

mRNA-1083.1 is a phase 2 stage product being developed by Moderna for SARS-CoV-2, Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT05827926. Target conditions include SARS-CoV-2, Influenza.

What happened to similar drugs?

4 of 20 similar drugs in SARS-CoV-2, Influenza were approved

Approved (4) Terminated (1) Active (16)
✅mRNA-1273 Variant-containing FormulationModernaApproved
✅mRNA-1273ModernaApproved
✅AZD1222AstraZenecaApproved
✅BNT162b2PfizerApproved
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1083ModernaPhase 3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05827926Phase 2Completed

Competing Products

20 competing products in SARS-CoV-2, Influenza

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1273ModernaPhase 1
0
mRNA-1283ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1273.214ModernaPhase 2
0
SPIKEVAXModernaPreclinical
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
SPIKEVAX BivalentModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
mRNA-1273ModernaPhase 2
0
mRNA-1073ModernaPhase 2
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1273.211ModernaPhase 3
0
SPIKEVAX (mRNA-1273)ModernaPreclinical
0
mRNA-1083ModernaPhase 2
0